IV immunoglobulin for acute lung injury and bacteremia in pseudomonas aeruginosa pneumonia

Critical Care Medicine

Volumn 44, Issue 1, 2016, Pages e12-e24

  Katoh, Hideya ^a   Yasumoto, Hiroaki ^a   Shimizu, Masaru ^a   Hamaoka, Saeko ^a   Kinoshita, Mao ^a   Akiyama, Koichi ^a   Sawa, Teiji ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

acute lung injury; intravenous immunoglobulin; PcrV; Pseudomonas aeruginosa; specific antibody; type III secretion system

Indexed keywords

CEFTAZIDIME; IMMUNOGLOBULIN G; MYELOPEROXIDASE; IMMUNOGLOBULIN;

ACUTE LUNG INJURY; ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LEUKOCYTE COUNT; LUNG EDEMA; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS PNEUMONIA; SURVIVAL; TYPE III SECRETION SYSTEM; ANIMAL; DRUG EFFECTS; PATHOGENICITY; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZATION;

ACUTE LUNG INJURY; ANIMALS; BACTEREMIA; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MICE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOM ALLOCATION;

EID: 84951068264     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001271     Document Type: Article

References (64)

1. Rello J, Lisboa T, Koulenti D, Respiratory infections in patients undergoing mechanical ventilation. Lancet Respir Med 2014 2 764 774
2. Tumbarello M, De Pascale G, Trecarichi EM, Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013 39 682 692
3. Ciofi Degli Atti M, Bernaschi P, Carletti M, An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect Dis 2014 14 494
4. Liew YX, Tan TT, Lee W, Risk factors for extreme-drug resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies. Am J Infect Control 2013 41 140 144
5. Jefferies JM, Cooper T, Yam T, Pseudomonas aeruginosa outbreaks in the neonatal intensive care unit-A systematic review of risk factors and environmental sources. J Med Microbiol 2012 61 1052 1061
6. Park YS, Lee H, Chin BS, Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: Risk factors and resistance mechanisms to carbapenems. J Hosp Infect 2011 79 54 58
7. Vettoretti L, Floret N, Hocquet D, Emergence of extensive- drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol Infect Dis 2009 28 1217 1222
8. Gómez-Zorrilla S, Camoez M, Tubau F, Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother 2014 58 5863 5870
9. Willmann M, Klimek AM, Vogel W, Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: A matched case control study. BMC Infect Dis 2014 14 650
10. Peña C, Gómez-Zorrilla S, Suarez C, Extensively drug-resistant Pseudomonas aeruginosa: Risk of bloodstream infection in hospitalized patients. Eur J Clin Microbiol Infect Dis 2012 31 2791 2797
11. Sawa T, The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: From bacterial pathogenesis to host response. J Intensive Care 2014 2 10
12. Sawa T, Shimizu M, Moriyama K, Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: A review. Crit Care 2014 18 668
13. Kurahashi K, Kajikawa O, Sawa T, Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999 104 743 750
14. Galán JE, Collmer A, Type III secretion machines: Bacterial devices for protein delivery into host cells. Science 1999 284 1322 1328
15. Hueck CJ, Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998 62 379 433
16. Lee CA, Type III secretion systems: Machines to deliver bacterial proteins into eukaryotic cells? Trends Microbiol 1997 5 148 156
17. Yahr TL, Goranson J, Frank DW, Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway. Mol Microbiol 1996 22 991 1003
18. Frank DW, The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol 1997 26 621 629
19. Hauser AR, The type III secretion system of Pseudomonas aeruginosa: Infection by injection. Nat Rev Microbiol 2009 7 654 665
20. Engel J, Balachandran P, Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol 2009 12 61 66
21. Finck-Barbançon V, Goranson J, Zhu L, ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997 25 547 557
22. Sato H, Frank DW, Hillard CJ, The mechanism of action of the Pseudomonas aeruginosa -encoded type III cytotoxin, ExoU. EMBO J 2003 22 2959 2969
23. Tamura M, Ajayi T, Allmond LR, Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU. Biochem Biophys Res Commun 2004 316 323 331
24. Pankhaniya RR, Tamura M, Allmond LR, Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit Care Med 2004 32 2293 2299
25. He J, Baldini RL, Déziel E, The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci U S A 2004 101 2530 2535
26. Sawa T, Yahr TL, Ohara M, Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999 5 392 398
27. Shime N, Sawa T, Fujimoto J, Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001 167 5880 5886
28. Holder IA, Neely AN, Frank DW, PcrV immunization enhances survival of burned Pseudomonas aeruginosa -infected mice. Infect Immun 2001 69 5908 5910
29. Frank DW, Vallis A, Wiener-Kronish JP, Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002 186 64 73
30. Faure K, Fujimoto J, Shimabukuro DW, Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa -induced acute lung injury in a rat model. J Immune Based Ther Vaccines 2003 1 2
31. Imamura Y, Yanagihara K, Fukuda Y, Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 2007 29 965 968
32. Song Y, Baer M, Srinivasan R, PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa -infected mice. Eur J Clin Microbiol Infect Dis 2012 31 1837 1845
33. Wang Q, Li H, Zhou J, PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury. Respir Physiol Neurobiol 2014 193 21 28
34. Baer M, Sawa T, Flynn P, An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009 77 1083 1090
35. Milla CE, Chmiel JF, Accurso FJ, KB001 Study Group Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2014 49 650 658
36. François B, Luyt CE, Dugard A, Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial. Crit Care Med 2012 40 2320 2326
37. Sawa T, Ito E, Nguyen VH, Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum Vaccin Immunother 2014 10 2843 2852
38. Nakamura K, Doi K, Okamoto K, Specific antibody in IV immunoglobulin for postsplenectomy sepsis. Crit Care Med 2013 41 e163 e170
39. Liu PV, The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo. J Infect Dis 1966 116 481 489
40. Sawa T, Ohara M, Kurahashi K, In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections. Infect Immun 1998 66 3242 3249
41. Sawa T, Corry DB, Gropper MA, IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997 159 2858 2866
42. Hauser AR, Cobb E, Bodi M, Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002 30 521 528
43. Roy-Burman A, Savel RH, Racine S, Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001 183 1767 1774
44. Lynch SV, Flanagan JL, Sawa T, Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV-Implications for anti-PcrV immunotherapy. Microb Pathog 2010 48 197 204
45. Feltman H, Schulert G, Khan S, Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001 147 2659 2669
46. Cho HH, Kwon KC, Kim S, Correlation between virulence genotype and fluoroquinolone resistance in carbapenem-resistant Pseudomonas aeruginosa. Ann Lab Med 2014 34 286 292
47. Sullivan E, Bensman J, Lou M, Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa. Crit Care Med 2014 42 48 56
48. Wong-Beringer A, Wiener-Kronish J, Lynch S, Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008 14 330 336
49. Tran QT, Nawaz MS, Deck J, Detection of type III secretion system virulence and mutations in gyrA and parC genes among quinolone-resistant strains of Pseudomonas aeruginosa isolated from imported shrimp. Foodborne Pathog Dis 2011 8 451 453
50. Agnello M, Wong-Beringer A, Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLoS One 2012 7 e42973
51. Di Rosa R, Pietrosanti M, Luzi G, Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis? Eur J Intern Med 2014 25 511 516
52. Laupland KB, Kirkpatrick AW, Delaney A, Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit Care Med 2007 35 2686 2692
53. Neilson AR, Burchardi H, Schneider H, Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 2005 20 239 249
54. Ohlsson A, Lacy JB, Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev 2013 7 CD001239
55. Pildal J, Gøtzsche PC, Polyclonal immunoglobulin for treatment of bacterial sepsis: A systematic review. Clin Infect Dis 2004 39 38 46
56. Turgeon AF, Hutton B, Fergusson DA, Meta-analysis: Intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007 146 193 203
57. Werdan K, Pilz G, Bujdoso O, Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med 2007 35 2693 2701
58. Oda S, Aibiki M, Ikeda T, Sepsis Registry Committee of The Japanese Society of Intensive Care Medicine The Japanese guidelines for the management of sepsis. J Intensive Care 2014 2 55
59. Kreymann KG, de Heer G, Nierhaus A, Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007 35 2677 2685
60. Peña C, Cabot G, Gómez-Zorrilla S, Spanish Network for Research in Infectious Diseases (REIPI) Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 2015 60 539 548
61. Ernst EJ, Hashimoto S, Guglielmo J, Effects of antibiotic therapy on Pseudomonas aeruginosa -induced lung injury in a rat model. Antimicrob Agents Chemother 1999 43 2389 2394
62. Sawa T, Kurahashi K, Ohara M, Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob Agents Chemother 1998 42 3269 3275
63. Holzheimer RG, Antibiotic induced endotoxin release and clinical sepsis: A review. J Chemother 2001 13 Spec No 1 159 172
64. Montor WR, Huang J, Hu Y, Genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays. Infect Immun 2009 77 4877 4886